Alimta approved in US for first-line use in lung cancer
This article was originally published in Scrip
Executive Summary
Lilly's chemotherapy drug Alimta (pemetrexed) has secured its biggest approval yet in the US, for the first-line treatment of locally-advanced and metastatic non-squamous non-small cell lung cancer (NSCLC).
You may also be interested in...
Alimta ANDA Products Hit Double Digits With Several Launches
Following patent expiry on 24 May, Alimta ANDA products have reached the US market, eating into a product that generated more than $1.2bn in sales last year.
2011 Scrip 100: A new look at cancer chemoprevention
The development of drugs to prevent cancer has lagged far behind the development of drugs, such as the statins, to prevent cardiovascular disease. But consideration of new, "personalised" clinical trial designs and an improved understanding of the biology of precancers, as well as new agents which target their molecular abnormalities, may make the field a more promising investment, says Malini Guha.
Janssen-Cilag's Xeplion recommended for EU approval for schizophrenia
Janssen-Cilag's (Johnson & Johnson) injectable drug Xeplion (paliperidone palmitate) has been recommended for European approval by the CHMP for the treatment of schizophrenia.